Laparoscopic secondary cytoreductive surgery: let’s not make the same assumptions

Ramírez, Pedro T.; Pareja, René

doi:10.1136/ijgc-2022-004255

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, groups are often not balanced in terms of type of recurrences, with a higher rate of extensive procedures in the open group, and there is little information about post-surgery therapies, which may have impacted the outcomes. Furthermore, MIS requires a high level of expertise and skill, especially in this group of patients, and should be performed in high-volume oncological centers with adequate experience in advanced surgical procedures [59].…”

Section: The Minimally-invasive Approachmentioning

confidence: 99%

Minimally-Invasive Secondary Cytoreduction in Recurrent Ovarian Cancer

Certelli,

Russo,

Palmieri

et al. 2023

Cancers

View full text Add to dashboard Cite

The role of secondary cytoreductive surgery (SCS) in the treatment of recurrent ovarian cancer (ROC) has been widely increased in recent years, especially in trying to improve the quality of life of these patients by utilising a minimally-invasive (MI) approach. However, surgery in previously-treated patients may be challenging, and patient selection and surgical planning are crucial. Unfortunately, at the moment, validated criteria to select patients for MI-SCS are not reported, and no predictors of its feasibility are currently available, probably due to the vast heterogeneity of recurrence patterns. The aim of this narrative review is to describe the role of secondary cytoreductive surgery and, in particular, minimally-invasive procedures, in ROC, analyzing patient selection, outcomes, criticisms, and future perspectives.

show abstract

Section: The Minimally-invasive Approachmentioning

confidence: 99%